Category Archives: Press Release

Global Report on Bacterial Conjunctivitis Drugs Market

The U.S. market for bacterial conjunctivitis drugs is highly fragmented in nature, with the presence of a large number of players operating in it, states a research study by Transparency Market Research. The number of new entrants is projected to rise substantially throughout the forecast period, resulting in a stiff competition among the leading players. F. Hoffmann-La Roche Ltd., Pfizer Inc., Novartis AG, Merck & Co. Inc., Santen Pharmaceutical Co. Ltd., Valeant Pharmaceuticals Int. Inc., Bayer AG are some of the leading players operating in the U.S. bacterial conjunctivitis drugs market. These players are emphasizing on collaborations and development of new products in order to enhance their presence and attain a leading position in the market. However, with the rising research and development activities and the improving production capacities, the market is likely to witness a downward trend in the near future.

According to the research study by Transparency Market Research, the U.S. market for bacterial conjunctivitis drugs is anticipated to reach a value of US$439.8 mn by the end of 2024 from US$473.3 mn in 2013. As a result, the market is expected to register a sluggish growth throughout the forecast period.

This 117 page report gives readers a comprehensive overview of the bacterial conjunctivitis drugs market. Browse through 27 data tables and 26 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/us-bacterial-conjunctivitis-drugs-market.html

Patent Expiry of Top Brands to Curtail Growth in U.S.

At present, the U.S. market for bacterial conjunctivitis drugs market is likely to witness diminishing growth, owing to the patent expiry of top branded formulations. The leading drug manufacturers in the market are anticipated to lose their share in the next few years. The rising competition among the players and the increasing preference of consumers towards herbal medications are some of the major factors that are estimated to hamper the growth of the U.S. bacterial conjunctivitis drugs market throughout the forecast period.

Macrolides, fluoroquinolones, and aminoglycosides are considered as the major classes of drugs that are used widely for curing bacterial conjunctivitis drugs market in the U.S. A significant demand for topical fluoroquinolones is expected among the leading drugs throughout the forecast period. However, the share of this segment is predicted to decrease, due to the upcoming patent expirations of the bestselling drugs in this class, including Moxeza, Vigamox, and Zymaxid. Nevertheless, the development of new effective drugs is expected to enhance the growth of the market throughout the forecast period.

Development of New Products to Encourage Growth

The increasing incidence of ophthalmic bacterial infection and the rising cases of bacterial conjunctivitis infection among different age groups are the key factors that are estimated to encourage the growth of the U.S. bacterial conjunctivitis drugs market in the next few years. In addition, the rising focus of the leading players on the production and designing of combination drugs is likely to accelerate the growth of the overall market in the next few years.

On the flip side, the increasing number of patent expirations is anticipated to restrict the growth of the bacterial conjunctivitis drugs market in the U.S. over the forecast period. In addition, the rising multi-drug resistant bacterial strains is anticipated to curtail the market’s growth in the coming years. As a result, the key players in the market are predicted to witness several challenges in the near future. Nevertheless, the increasing focus on the implementation of product development partnerships business models is likely to generate promising growth opportunities for key players operating in the bacterial conjunctivitis drugs market in the U.S.

Request a sample of this report to know what opportunities will emerge in the rapidly evolving bacterial conjunctivitis drugs market during 2012 – 2024: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=12323

This information is based on the findings of a research report published by Transparency Market Research (TMR), titled “Bacterial Conjunctivitis Drugs Market (Drug Class – Fluoroquinolones (Ciprofloxacin, Ofloxacin, Levofloxacin, Moxifloxacin, Gatifloxacin, Besifloxacin), Aminoglycosides (Tobramycin, Gentamycin), Macrolides (Erythromycin, Azithromycin)) – U.S. Industry Analysis, Pipeline Assessment, Size, Share, Growth, Trends and Forecast 2012 – 2024.”

 

Mesenchymal Stem Cells Market: Current status and future trends

Stem cells are specialized cells which have the capability of renewing themselves through cell division and differentiate into multi-lineage cells. Mesenchymal stem cells (MSCs) are non- hematopoietic, multipotent adult stem cells which can be isolated from bone marrow, cord blood, fat tissue, peripheral blood, fallopian tube, and fetal liver and lung tissue. Mesenchymal stem cells have the capacity to differentiate into mesodermal lineages, such as chondrocytes, adipocytes, and osteocytes, and non-mesodermal lineages such as ectodermal (neurocytes) and endodermal lineages (hepatocytes). These stem cells have specific features such as multilineage potential, secretion of anti-inflammatory molecules, and immunomodulation. These cells have emerged as promising therapeutic agents for regenerating skeletal tissues such as damaged bone and cartilage tissues and treatment of chronic diseases owing to their specific features.

Obtain Report Details: http://www.transparencymarketresearch.com/mesenchymal-stem-cells-market.html

The global mesenchymal stem cells market is expected to be driven by the increasing clinical application of mesenchymal stem cells for the treatment of chronic diseases, bone and cartilage diseases, and autoimmune diseases. Studies have shown that these stem cells enhance the angiogenesis in myocardium and allow the reduction of myocardial fibrotic area. The pre-clinical studies for using mesenchymal stem cells in treatment of cardiovascular diseases, liver diseases, and cancer are projected to create new market opportunities for mesenchymal stem cells. Mesenchymal stem cells also produce anti-inflammatory molecules which modulate humoral and cellular immune responses. Features of these stem cells such as ease of isolation, regenerative potential, and immunoregulatory, the mesenchymal stem cell therapy has emerged as a promising tool for the treatment of chronic diseases, degenerative, inflammatory, and autoimmune diseases. Clinical studies are exploring MSCs for various conditions such as orthopedic injuries, graft versus host disease following bone marrow transplantation, and genetic modification of MSCs to overexpress antitumor genes for use as anticancer therapy, which are exhibiting new opportunities in therapeutic area. However, the mesenchymal stem cell research studies are tedious, lengthy, and complex. In some cases, due to some adverse effects transplanted mesenchymal stem cells rapidly removed from the body which limits use of stem cells in therapeutic treatments. The conflicting results and regulatory compliances for approvals may also hamper the growth of this market.

The global mesenchymal stem cells market is segmented on the basis of source of isolation, end-user, and region. Stem cells are isolated from the bone marrow, peripheral blood, lung tissue, umbilical cord blood, amniotic fluids, adipose tissues, and synovial tissues. Traditionally the MSC’s were isolated from bone marrow aspiration which is associated with risk of infection and painful for the patient. The MSC’s from adipose tissues are usually isolated from the biological material generated during liposuction, lipectomy procedures by using collagenase enzymatic digestion followed by centrifugation and washing. In terms of end-user, the market is segmented into clinical research organizations, biotechnological companies, medical research institutes, and hospitals.

Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=26735

Geographically, the global mesenchymal stent cells market is distributed over North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market and is projected to continue its dominance in terms of market share during the forecast period owing to high R&D expenditure, availability of advanced research facilities and skilled professionals, and government initiatives. Europe is the second largest market after North America. The Asia Pacific market is projected to expand at a high CAGR during the forecast period due to increased R&D budgets in Japan, China, and India.

Key global players operating in the mesenchymal stem cells market include R&D Systems, Inc., Cell Applications, Inc., Axol Bioscience Ltd., Cyagen Biosciences Inc., Cytori Therapeutics Inc., Stemcelltechnologies Inc., BrainStorm Cell Therapeutics, Stemedica Cell Technologies, Inc., and Celprogen, Inc.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Contact us:

Transparency Market Research

90 State Street,

Suite 700,

Albany

NY – 12207

United States

Tel: +1-518-618-1030

USA – Canada Toll Free 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/

Systemic Antiviral Pharmaceuticals Market Outlook and Forecast up to 2023

Global Systemic Antiviral Pharmaceuticals Market

Antiviral drugs are a class of medication that inhibits the development of infection causing viruses. Like antibiotics, specific antiviral drugs are used against specific viruses. As viruses share most of the metabolic processes with the host cell, it is difficult to commercialize new medications that are selective in action. The presently available antiviral agents either act as DNA polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, immunomodulators, neuraminidase inhibitors or integrase strand transfer inhibitors. The currently available antiviral drugs target four main kinds of viruses:

  • Herpes
  • Hepatitis
  • Influenza
  • Human Immunodeficiency Virus (HIV)

Obtain Report Details: http://www.transparencymarketresearch.com/systemic-antiviral-pharmaceuticals-market.html

Global Systemic Antiviral Pharmaceuticals Market: Segmentation

Antiviral drugs can be administered by various methods such as topical or local application, systemic delivery, controlled delivery and targeted delivery. Systemic drug delivery is relatively safe and effective for the treatment than topical agents. In recent times, systemic delivery method is gaining attention owing to its higher therapeutic efficacy and bioavailability. The demand for products with systemic application is high especially in the treatment for chronic viral infections such as hepatitis and HIV infection.

Based on the class of antiviral drugs, the global systemic antiviral pharmaceuticals market is segmented into DNA polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, immunomodulators, interferon, neuraminidase inhibitors and integrase strand transfer inhibitors. Increasing resistance to M2 inhibitors has shifted the focus towards neuraminidase inhibitors for the treatment of influenza. Neuraminidase inhibitors class of drugs includes Oseltamivir and Zanamivir which are administered through systemic route. Herpes virus can be treated using medications such as Acyclovir, Brivudin, Cidofovir, Famciclovir, Fomivirsen, Foscarnet, Ganciclovir, Penciclovir, Valacyclovir, Vidarabine and Valganciclovir. Treatment for hepatitis includes administration of either or combination of the following medications:

  • Interferons
  • Ribavarin
  • Nucleoside analogues such as Adefovir, Emtricitabine, Entecavir, Lamivudine, Telbivudine and Tenofovir
  • Protease inhibitors such as Boceprevir, Telaprevir,

Based on the disease type, the global systemic antiviral pharmaceuticals market can be analyzed as herpes, hepatitis, influenza and HIV infection. Recent advancements in the field of antiviral treatment for herpes infection have inclined the ophthalmologists to treat severe ocular infection caused by herpes virus. In addition, the acute retinal necrosis (ARN) syndrome caused by herpes virus and retinal infection caused by cytomegalovirus is also treated using systemic antiviral drugs. Vidarabine, Acyclovir, Ganciclovir, and Foscarnet are the four major systemic antivral drugs used in the treatment of ophthalmic infections. Rising incidence of herpes virus infections, as well as the rising epidemic of HIV infections has led to increase in ophthalmic infections which drive the demand for systemic antiviral pharmaceuticals.

Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=12287

Global Systemic Antiviral Pharmaceuticals Market: Geographical Dynamics

The demand for systemic antiviral pharmaceuticals is high in regions with high prevalence of herpes, influenza, hepatitis and HIV infection. According to World Health Organization (WHO), worldwide 35.3 million people were living with HIV infection at the end of 2012. The prevalence is high in the African region where nearly one in 20 adults is living with HIV infection. Further, the prevalence of herpes simplex virus type 2 is high in Africa, North America and some parts of Asia-Pacific. Early and effective treatment is therefore the primary need in these regions. Hence, the demand for systemic antiviral pharmaceuticals will increase with growing incidence of viral infections.

Some of the major players in the systemic antiviral pharmaceuticals market are GlaxoSmithKline plc, Bristol-Myers Squibb, Gilead Sciences, F. Hoffmann-La Roche Ltd., Pfizer, Inc., Boehringer Ingelheim, Abbott Laboratories and Merck & Co., Inc.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

 

Urinary Tract Stenting Market Dynamics and Opportunities Report by Transparency Market Research

Urine is normally carried from the kidneys to the bladder through long, narrow, muscular tubes called ureters. The passage of urine may become difficult if the ureter becomes obstructed due to conditions such as tumors, infections, kidney stone, etc. For such conditions, the physicians place an artificial tube, known as ureteral stent, intended to restore the flow of the bladder. Aging is the most common factor that leads to several types of urology diseases. The global aging population is a direct indication of the possible rise in the patients suffering with urological diseases. With the increasing conditions that obstruct the flow of urine, the use of urological stents have become the most fundamental and valuable technique in the urological practice.

Obtain Report Details: http://www.transparencymarketresearch.com/urinary-tract-stenting-market.html

A ureteral stent is specially designed a soft tube 10-12 inches in length that is placed in the ureter for draining urine from the kidney to the urinary bladder. These stents are coiled at both the end to stay in place in the urinary system and therefore also known as JJ stent, pig-tail stent of double J stent. Normally a person can have ureteral stents for not more than 3 to 6 months. If left for longer duration, there is a possibility of stone formation which makes removal of stents difficult. If a patient is required to have stent for a longer duration, he must be admitted in the hospital for stent change. This is a serious limitation for the usage ureteral stent. Several companies operating in the market are trying to overcome the issue of biofilm formation and mineralogical encrustation. Furthermore, there are ongoing research activities in the global urinary tract stenting market to modify the design, discovering novel stent coating and the basic composition materials of the stent. Usage of metal stents in urology is being recommended by some physicians which have not yet become a widespread practice. Some of the advancements required for the industry include anti-body coated stents, nanotube coating, radioactive stents, and absorbable magnesium metal stent. The successful trials of the technologies have a potential to drastically change the existing market dynamics in the global urinary stenting market.

The global market for urinary tract stenting can be segmented on the basis of application of urology stents into kidney stones treatment. The major segments in which urological stents are used include procedures such as lithotripsy, ureteroscopy, ureteroenoscopy, and percutaneous nephrolithotomy. Based on the procedures of removing the obstruction in the ureter, the market can be segmented into ureteral stenting, prostate stenting and urethral stenting.

Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=11072

Based on the geography, the global urinary tract stenting market is segmented into four major regions, namely, North America, Europe, Asia-Pacific and Rest of the World. More than 2 million people in the U.S. are annually diagnosed for the presence of kidney stone. The number of people suffering from similar diseases is even higher in the Asia-Pacific and Rest of the World. The rising number of kidney stone patients in the world is expected to increase the number of treatment procedures at a faster rate than before eventually increasing the demand for the urinary tract stents. As the economic conditions in the emerging nations such as China, India, and Brazil are expected to improve in the near future, most of the market growth will be fuelled by demand from these countries.

Some of the key companies operating in the global urinary tract stenting market include Boston Scientific Corporation, C. R. Bard, Inc., Cook Medical, Inc., and Medline Industries, Inc., Pnn Medical A/S, and Allium Medical Solutions Ltd.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Contact us:

Transparency Market Research

90 State Street,

Suite 700,

Albany

NY – 12207

United States

Tel: +1-518-618-1030

USA – Canada Toll Free 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com/

Huntington’s Disease Therapeutics Market: Aggressive Research Activities Stimulating Market Growth

Huntington’s disease (HD) is an autosomal dominant hereditary disorder of the central nervous system. The disease results in progressive degeneration of the brain cells. A physician named George Huntington described the disorder in detail as hereditary chorea in 1872. Thus, earlier it was known as Huntington’s chorea or HC. Huntington’s disease usually develops symptoms in adulthood between the age of 30 years and 40 years. In case the symptoms of the disease are developed before the age of 20 years, it is referred as juvenile Huntington’s disease. Both men and women are susceptible to this disease. Studies show that one in every 10,000 people in America has HD and more than 250,000 people are at risk of inheriting the disease from a parent.

Obtain Report Details: http://www.transparencymarketresearch.com/huntingtons-disease-therapeutics-market.html

The disease causes a wide range of symptoms in an affected person. Primarily, it leads to difficulty in motor control (movement), cognition (thinking), and behavior. Motor problems include impairments in voluntary movements as well as onset of uncontrolled involuntary jerking. People suffering from HD also have muscle problems such as muscle contracture (dystonia) or rigidity, impaired gait, posture, and balance. Loss of motor control hampers a person’s daily activities and causes difficulty in living a normal life. The disease also leads to speech and swallowing problems (dysphagia). These occur when the centers of the motor or cognitive control responsible for these functions are affected. A significant behavior and cognition disorder associated with Huntington’s disease is depression that results due to brain injury and loss of brain function.

Although medical science has no cure for this disease, the symptoms of this disease can be detected and treated. Drugs to treat movement disorders include tetrabenazine (Xenazine), antipsychotic drugs such as haloperidol (Haldol), chlorpromazine, and others. Antidepressants such as escitalopram (Lexapro), fluoxetine (Prozac, Sarafem), citalopram (Celexa), and sertraline (Zoloft) are given as treatment. Development in scientific research has led to increased awareness about Huntington’s disease. This is one of the key drivers for the growth of the Huntington’s disease therapeutics market. In addition, increased prevalence of the disease is a key growth driver of the market. Unmet medical needs have driven scientists and researchers to develop therapy for Huntington’s disease, which in turn is likely to drive the global market. Increased investment by many pharmaceutical companies in the research and development sector to develop innovative and curative drugs for the disease is driving the growth of the global market. Further, alternative therapies, including speech therapy, psychotherapy, and physiotherapy, increase the potential of the market growth for Huntington’s disease therapeutics.

Fill the form for an exclusive sample of this report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=26753

Geographically, the global Huntington’s disease therapeutics market is distributed over North America, Europe, APAC, and Latin America. North America dominates the global market due to increased awareness about the disease. In the North America market, the U.S. holds the largest market share, followed by Canada. Europe accounts for the second largest market globally. In Europe, countries such as France, Germany, the U.K., and Spain contribute major shares of the market. Increasing awareness about the disease along with growing infrastructure for scientific research is projected to lead to market establishment for Huntington’s disease therapeutics in other parts of the world such as China, India, Japan, Africa, Argentina, and Brazil.

Key players contributing highest market shares include Teva Pharmaceutical Industries, Alnylam Pharmaceuticals, Inc., AmpliPhi Biosciences Corp, Pfizer, Lundbeck, Prana Biotechnology Ltd., Valeant Pharmaceuticals International Inc., Cortex Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, GlaxoSmithKline, Auspex Pharmaceuticals, Ceregene Inc., SOM Biotech, Siena Biotech, Raptor Pharmaceutical, Palobiofarma, and Ipsen.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.